Marshall Urist - 05 Aug 2026 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Reporting relationship: EVP, Research & Investments
Issuer ticker: RPRX
Reported as of: 05 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Aug 2026, 17:11:13 UTC
Prior SEC filing: 02 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist

Key filing fact

Marshall Urist filed Form 4 for Royalty Pharma plc (RPRX) on 07 Aug 2026.

Key facts

This page summarizes Marshall Urist's Form 4 filing for Royalty Pharma plc (RPRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Aug 2026, 17:11.

Change

Previous filing in this sequence was filed on 02 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001838139 Primary reporting owner

Urist Marshall

Relationship: EVP, Research & Investments
Address: C/O ROYALTY PHARMA PLC, 110 EAST 59TH STREET, NEW YORK
Signature: /s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist
Signature date: 07 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RPRX transaction

Class A Ordinary Shares

Award

Transaction value
Shares: +8,252
Change %
Price: $0.000000^*
Shares after: 8,252
Date: 05 Aug 2026
Ownership: Direct
Footnotes: F1

RPRX holding

Class A Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 19,020
Date: 05 Aug 2026
Ownership: By IRA

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RPRX transaction Derivative

LP interests in RPI US Partners 2019, LP

Gift

Transaction value
Shares: -3,000
Change %: -1.2%
Price: $0.000000^*
Shares after: 244,412
Date: 07 Aug 2026
Ownership: By Sandy Lamm LLC
Underlying class: Class A Ordinary Shares
Underlying amount: 30,000
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Footnote F2

No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.

Footnote F3

Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

SEC remarks

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person holds Class E Ordinary Shares of Holdings exchangeable into 1,356,528 Class A Ordinary Shares. Class E Ordinary Shares of Holdings are subject to vesting conditions.